---
title: Pneumococcal 13 valent Conjugate Vaccine
description: >-
  - **Medical Conditions:** Pneumococcal 13-valent Conjugate Vaccine (PCV13) is
  prescribed for active immunization against invasive pneumococcal disease
  (e.g., septicemia, meningitis) and pneumonia caused by *Streptococcus
  pneumoniae* serotypes included in the vaccine (1, 3, 4, 5, 6A, 6B, 7F, 9V,
  1...
is_banned: false
lastModified: '2025-09-22T17:21:53.929Z'
faqs:
  - q: >-
      What is the recommended dosage for Pneumococcal 13 valent Conjugate
      Vaccine?**


      **A:** Refer to the detailed Dosage section above. It varies based on age
      and prior vaccination history.
    a: >-
      A:** Refer to the detailed Dosage section above. It varies based on age
      and prior vaccination history.
  - q: >-
      Can PCV13 be given during pregnancy?**


      **A:** Data are insufficient to determine the risks. Only administer
      during pregnancy if potential benefits outweigh the risks.
    a: >-
      A:** Data are insufficient to determine the risks. Only administer during
      pregnancy if potential benefits outweigh the risks.
  - q: >-
      What are the common side effects of PCV13?**


      **A:** Common side effects include injection site reactions, drowsiness,
      fever, and headache.
    a: >-
      A:** Common side effects include injection site reactions, drowsiness,
      fever, and headache.
  - q: |-
      How is PCV13 administered?**

      **A:** PCV13 is administered intramuscularly (IM).
    a: 'A:** PCV13 is administered intramuscularly (IM).'
  - q: |-
      Can PCV13 be given with other vaccines?**

      **A:** Yes, generally. However, different injection sites should be used.
    a: 'A:** Yes, generally. However, different injection sites should be used.'
  - q: >-
      Is PCV13 effective against all pneumococcal serotypes?**


      **A:** No, PCV13 only protects against the 13 serotypes included in the
      vaccine.
    a: >-
      A:** No, PCV13 only protects against the 13 serotypes included in the
      vaccine.
  - q: >-
      What should I do if a patient experiences an allergic reaction?**


      **A:**  Manage allergic reactions as appropriate, including administering
      epinephrine for anaphylaxis.
    a: >-
      A:**  Manage allergic reactions as appropriate, including administering
      epinephrine for anaphylaxis.
  - q: >-
      How long does immunity from PCV13 last?**


      **A:** The duration of immunity is not precisely known, but antibody
      levels persist for several years after vaccination.
    a: >-
      A:** The duration of immunity is not precisely known, but antibody levels
      persist for several years after vaccination.
  - q: |-
      Can PCV13 be given to immunocompromised patients?**

      **A:**  Yes, but the immune response may be reduced.
    a: 'A:**  Yes, but the immune response may be reduced.'
  - q: >-
      Does PCV13 treat existing pneumococcal infections?**


      **A:** No, PCV13 is a vaccine for prevention, not treatment. It does not
      treat active infections.
    a: >-
      A:** No, PCV13 is a vaccine for prevention, not treatment. It does not
      treat active infections.
---
## **Usage**

- **Medical Conditions:** Pneumococcal 13-valent Conjugate Vaccine (PCV13) is prescribed for active immunization against invasive pneumococcal disease (e.g., septicemia, meningitis) and pneumonia caused by *Streptococcus pneumoniae* serotypes included in the vaccine (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). In children aged 6 weeks through 5 years, it's also used to prevent otitis media caused by specific serotypes.
- **Pharmacological Classification:**  Vaccine (Bacterial, inactivated)
- **Mechanism of Action:** PCV13 stimulates the immune system to produce antibodies against the 13 *S. pneumoniae* serotypes contained in the vaccine. These antibodies provide active immunity, protecting against future infections by these specific serotypes.


## **Alternate Names**

- Pneumococcal 13-valent diphtheria conjugate vaccine
- 13vPCV
- PCV13
- **Brand Names:** Prevnar 13, Prevenar 13


## **How It Works**

- **Pharmacodynamics:** PCV13 triggers an immune response leading to the production of serotype-specific antibodies.  This immune response mimics natural infection without causing the disease. 
- **Pharmacokinetics:** After intramuscular injection, the vaccine components are processed by antigen-presenting cells, leading to antibody production. The pharmacokinetic properties of individual components are not typically measured. The relevant measure is the immune response generated (antibody titers).
- **Mode of Action:** PCV13 contains capsular polysaccharides from the 13 pneumococcal serotypes conjugated to diphtheria CRM197 protein. Conjugation enhances the immunogenicity of the polysaccharides, particularly in young children.  The conjugate vaccine elicits T-cell dependent B-cell responses, resulting in immunological memory and long-lasting immunity.
- **Receptor Binding/Enzyme Inhibition/Neurotransmitter Modulation:** Not applicable for vaccines.
- **Elimination Pathways:** The conjugated polysaccharides and protein carrier are degraded through normal physiological processes.


## **Dosage**

### **Standard Dosage**

#### **Adults (18 years and older):**

- 0.5 mL IM, single dose


#### **Children:**

- **6 weeks to 6 months:**  A series of four 0.5 mL doses IM administered at 2, 4, 6, and 12-15 months of age. 
- **7 months to 5 years:** Varies depending on prior PCV13 doses received. Consult specific guidelines based on age and vaccination history.
- **6 through 17 years:** One single dose of 0.5 mL IM


#### **Special Cases:**

- **Elderly Patients:** Standard adult dose.
- **Patients with Renal Impairment:** No dose adjustment.
- **Patients with Hepatic Dysfunction:** No dose adjustment.
- **Patients with Comorbid Conditions:** Standard dosing unless specific contraindications exist based on the comorbid condition.



### **Clinical Use Cases:**  PCV13 is for preventive immunization, not for use during acute medical situations like intubation, surgical procedures, mechanical ventilation, ICU use, or emergency situations.  


### **Dosage Adjustments:** Generally, no dosage adjustments are needed for renal/hepatic dysfunction, metabolic disorders, or genetic polymorphisms.


## **Side Effects**

### **Common Side Effects:**

- Injection site reactions (pain, redness, swelling)
- Drowsiness, irritability (infants)
- Decreased appetite
- Fever
- Headache


### **Rare but Serious Side Effects:**

- Allergic reactions (anaphylaxis)
- Seizures (febrile)


### **Long-Term Effects:** Not typically associated with long-term side effects.


### **Adverse Drug Reactions (ADR):**  Anaphylaxis requires immediate medical intervention.


## **Contraindications**

- Severe allergic reaction (anaphylaxis) to a previous dose of PCV13 or any of its components (including diphtheria toxoid).



## **Drug Interactions**

- Immunosuppressive therapy may reduce the immune response to PCV13.
- Concomitant administration with other vaccines is generally well-tolerated, but separate injection sites should be used.


## **Pregnancy and Breastfeeding**

- **Pregnancy Safety Category:** Data on use in pregnant women are insufficient to inform vaccine-associated risks.  Use only if clearly needed.
- **Breastfeeding:**  Data are limited; potential excretion of vaccine components into breast milk and effects on breastfed infants are unknown.


## **Drug Profile Summary**

- **Mechanism of Action:** Induces antibody production against 13 *S. pneumoniae* serotypes.
- **Side Effects:**  Injection site reactions, drowsiness, fever, headache. Rarely, anaphylaxis or seizures.
- **Contraindications:**  Previous severe allergic reaction to PCV13 or components.
- **Drug Interactions:** Immunosuppressants may reduce response.
- **Pregnancy & Breastfeeding:**  Limited data; use with caution.
- **Dosage:**  See detailed section above.
- **Monitoring Parameters:** Monitor for signs of allergic reaction, especially after the first dose.


## **Popular Combinations**

 PCV13 is often given in combination with other routine childhood vaccinations.  


## **Precautions**

- Screen for contraindications before administration.
- Postpone vaccination during acute febrile illness.
- Observe patient for allergic reactions after administration.
- Ensure proper storage and handling of the vaccine.


## **FAQs (Frequently Asked Questions)**


### **Q1: What is the recommended dosage for Pneumococcal 13 valent Conjugate Vaccine?**

**A:** Refer to the detailed Dosage section above. It varies based on age and prior vaccination history.


### **Q2: Can PCV13 be given during pregnancy?**

**A:** Data are insufficient to determine the risks. Only administer during pregnancy if potential benefits outweigh the risks.


### **Q3: What are the common side effects of PCV13?**

**A:** Common side effects include injection site reactions, drowsiness, fever, and headache.


### **Q4:  How is PCV13 administered?**

**A:** PCV13 is administered intramuscularly (IM).


### **Q5: Can PCV13 be given with other vaccines?**

**A:** Yes, generally. However, different injection sites should be used.


### **Q6: Is PCV13 effective against all pneumococcal serotypes?**

**A:** No, PCV13 only protects against the 13 serotypes included in the vaccine.


### **Q7: What should I do if a patient experiences an allergic reaction?**

**A:**  Manage allergic reactions as appropriate, including administering epinephrine for anaphylaxis.  


### **Q8: How long does immunity from PCV13 last?**

**A:** The duration of immunity is not precisely known, but antibody levels persist for several years after vaccination.  


### **Q9: Can PCV13 be given to immunocompromised patients?**

**A:**  Yes, but the immune response may be reduced.


### **Q10:  Does PCV13 treat existing pneumococcal infections?**

**A:** No, PCV13 is a vaccine for prevention, not treatment. It does not treat active infections.
